Facet-related back pain – a common but hard-to-recognise cause
Back pain is among the most common complaints in our society. One often overlooked cause is facet-related back pain, which originates from the small vertebral joints known as facet joints. These joints can trigger pain as a result of wear and tear, overstrain, or instability – particularly in the cervical (neck) and lumbar (lower back) spine.

Why the diagnosis is so difficult
Imaging techniques such as X-rays or MRI often reveal degenerative changes, but these do not always correspond to the actual pain. To provide clarity, at ISSZ we use diagnostic injections: by selectively numbing the suspected joints or nerve branches, it is possible to determine whether the facet joints are the source of the pain.
Typical complaints
- Chronic pain in the neck or lumbar region
- Intensification of pain when getting up, overstretching, or twisting
- Morning stiffness
- Reduced mobility and muscular tension
These symptoms can significantly impair quality of life and highlight the importance of a targeted diagnostic evaluation.
Treatment at ISSZ
The therapy is tailored to the severity and the individual situation. Initially, conservative measures are usually recommended, such as physiotherapy, targeted exercises, ergonomic adjustments, and, if necessary, medication.
If the pain is not sufficiently relieved, further options are available:
Injections (intra-articular or medial branch block) can provide short-term pain reduction while also contributing to diagnostic confirmation.
Radiofrequency ablation (RFA) has proven to be particularly effective. In this procedure, pain-transmitting nerve fibres are specifically cauterised. Many patients report a significant improvement that can last for up to twelve months.
Future prospects
New regenerative approaches such as PRP (platelet-rich plasma) are currently being investigated scientifically. They show promising potential, but the evidence is not yet sufficient for them to be recommended as standard therapy.
Subscribe to Newsletter
We’d be happy to share more about us and our services in the next newsletter and on www.issz.ch.
Current Affairs
Further News & Publications
Team – Dr. med. T. Tessmann #NewDoctor #NewPainSpecialist
From June, Dr. Tobias Tessmann will join ISSZ. He already worked as a resident in anesthesiology at Spital Lachen from 2019-2021 together with Dr. J.
Certification as an SSIPM Training Centre Pain Clinic B
We recently announced that we would apply for certification as an SSIPM training centre “Pain Clinic B”. We are now very pleased to have received
Cooperation with the Institute for Interventional Pain Medicine Zurich AG (IISZ)
Similar to the long-standing, close friendship and professional relationship between Jan Ludwigs and Daniel Friis, the connection between the ISSZ and the Institute for Interventional
Suzetrigin: A Novel Pain Medication in Switzerland
Suzetrigin (brand name: Journavx™) is an innovative, non-opioid analgesic that was approved in January 2025 by the U.S. FDA for the treatment of moderate to
Pulsed Radiofrequency Treatment (pRF)
Die gepulste Radiofrequenz-Behandlung (pRF) stellt eine minimalinvasive, nicht-destruktive Methode zur Behandlung
chronischer Schmerzen dar. Im Gegensatz zur thermischen Radiofrequenzablation, die durch Hitzeeinwirkung Nerven
1 year of Interventional Pain Medicine SZ AG – Less pain, more quality of life
On 3 May 2025, we celebrated the one-year anniversary of the Institute for Interventional Pain Medicine SZ AG – a significant milestone on our journey

Facet-related back pain – a common but hard-to-recognise cause
Facet-related back pain – a common but hard-to-recognise cause Back pain is among the most common complaints in our society. One often overlooked cause is
Team – Dr. med. T. Tessmann #NewDoctor #NewPainSpecialist
From June, Dr. Tobias Tessmann will join ISSZ. He already worked as a resident in anesthesiology at Spital Lachen from 2019-2021 together with Dr. J.
Certification as an SSIPM Training Centre Pain Clinic B
We recently announced that we would apply for certification as an SSIPM training centre “Pain Clinic B”. We are now very pleased to have received
Cooperation with the Institute for Interventional Pain Medicine Zurich AG (IISZ)
Similar to the long-standing, close friendship and professional relationship between Jan Ludwigs and Daniel Friis, the connection between the ISSZ and the Institute for Interventional
Suzetrigin: A Novel Pain Medication in Switzerland
Suzetrigin (brand name: Journavx™) is an innovative, non-opioid analgesic that was approved in January 2025 by the U.S. FDA for the treatment of moderate to
Pulsed Radiofrequency Treatment (pRF)
Die gepulste Radiofrequenz-Behandlung (pRF) stellt eine minimalinvasive, nicht-destruktive Methode zur Behandlung
chronischer Schmerzen dar. Im Gegensatz zur thermischen Radiofrequenzablation, die durch Hitzeeinwirkung Nerven